Literature DB >> 23000221

Role of antibody dependent cell mediated cytotoxicity (ADCC) in Sm-p80-mediated protection against Schistosoma mansoni.

Workineh Torben1, Gul Ahmad, Weidong Zhang, Stewart Nash, Loc Le, Souvik Karmakar, Afzal A Siddiqui.   

Abstract

Schistosomiasis is a major health problem in the developing world and for international travelers to the endemic countries. Existing strategies to control schistosomiasis have had limited successes so far. The addition of an effective vaccine in existing control measures would be greatly beneficial in reducing the impact of the disease. In this regard, Sm-p80 mediated protection against intestinal schistosomiasis caused by Schistosoma mansoni has been observed to be promising in two animal models of infection and disease. In this study, the role of antibody dependent cell mediated cytotoxicity (ADCC) was deciphered in Sm-p80-mediated protection especially in the elimination of lung stage schistosomula. This was achieved using lung lavage cells and lung cells that were isolated from mice immunized with and without Sm-p80 formulated in a recombinant vaccine formulation. Significant differences were observed in cytotoxicity assays using immune sera with the lung lavage cells which showed 51% more killing of schistosomula and elevated levels of nitric oxide in the supernatants were detected compared to controls.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23000221      PMCID: PMC3488153          DOI: 10.1016/j.vaccine.2012.09.026

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  49 in total

1.  Neglected tropical diseases: moving beyond mass drug treatment to understanding the science.

Authors:  Adel Mahmoud; Elias Zerhouni
Journal:  Health Aff (Millwood)       Date:  2009 Nov-Dec       Impact factor: 6.301

2.  Antibody-dependent killing of Schistosoma mansoni schistosomula in vitro by starch-elicited murine macrophages. Critical role of the cell surface integrin Mac-1 in killing mediated by the anti-Mr 16,000 mAb B3A.

Authors:  D A Vignali; Q D Bickle; P Crocker; M G Taylor
Journal:  J Immunol       Date:  1990-05-15       Impact factor: 5.422

3.  Enhancement of Sm-p80 (large subunit of calpain) induced protective immunity against Schistosoma mansoni through co-delivery of interleukin-2 and interleukin-12 in a DNA vaccine formulation.

Authors:  Afzal A Siddiqui; Troy Phillips; Hugues Charest; Ron B Podesta; Martha L Quinlin; Justin R Pinkston; Jenny D Lloyd; Janet Pompa; Rachael M Villalovos; Michelle Paz
Journal:  Vaccine       Date:  2003-06-20       Impact factor: 3.641

4.  Protective effects of Sm-p80 in the presence of resiquimod as an adjuvant against challenge infection with Schistosoma mansoni in mice.

Authors:  Gul Ahmad; Weidong Zhang; Workineh Torben; Zahid Noor; Afzal A Siddiqui
Journal:  Int J Infect Dis       Date:  2010-07-13       Impact factor: 3.623

5.  Post lung-stage schistosomula of Schistosoma mansoni exhibit transient susceptibility to macrophage-mediated cytotoxicity in vitro that may relate to late phase killing in vivo.

Authors:  E J Pearce; S L James
Journal:  Parasite Immunol       Date:  1986-09       Impact factor: 2.280

6.  Neglected tropical disease vaccines.

Authors:  Peter J Hotez; Ami Shah Brown
Journal:  Biologicals       Date:  2009-03-17       Impact factor: 1.856

7.  Effects of recombinant tumour necrosis factor on antibody-dependent eosinophil-mediated damage to Schistosoma japonicum larvae.

Authors:  T Janecharut; H Hata; H Takahashi; S Yoshida; H Saito; S Kojima
Journal:  Parasite Immunol       Date:  1992-11       Impact factor: 2.280

8.  Sm-p80-based DNA vaccine formulation induces potent protective immunity against Schistosoma mansoni.

Authors:  G Ahmad; W Torben; W Zhang; M Wyatt; A A Siddiqui
Journal:  Parasite Immunol       Date:  2009-03       Impact factor: 2.280

Review 9.  Time to set the agenda for schistosomiasis elimination.

Authors:  David Rollinson; Stefanie Knopp; Sarah Levitz; J Russell Stothard; Louis-Albert Tchuem Tchuenté; Amadou Garba; Khalfan A Mohammed; Nadine Schur; Bobbie Person; Daniel G Colley; Jürg Utzinger
Journal:  Acta Trop       Date:  2012-05-10       Impact factor: 3.112

10.  Enhancing schistosomiasis control strategy for zimbabwe: building on past experiences.

Authors:  Moses J Chimbari
Journal:  J Parasitol Res       Date:  2012-05-08
View more
  12 in total

Review 1.  Development of a schistosomiasis vaccine.

Authors:  Adebayo J Molehin; Juan U Rojo; Sabrina Z Siddiqui; Sean A Gray; Darrick Carter; Afzal A Siddiqui
Journal:  Expert Rev Vaccines       Date:  2016-01-13       Impact factor: 5.217

2.  Functions of Antibodies.

Authors:  Donald N Forthal
Journal:  Microbiol Spectr       Date:  2014-08-15

3.  Longevity of Sm-p80-specific antibody responses following vaccination with Sm-p80 vaccine in mice and baboons and transplacental transfer of Sm-p80-specific antibodies in a baboon.

Authors:  Weidong Zhang; Gul Ahmad; Loc Le; Juan U Rojo; Souvik Karmakar; Kory A Tillery; Workineh Torben; Raymond T Damian; Roman F Wolf; Gary L White; David W Carey; Darrick Carter; Steven G Reed; Afzal A Siddiqui
Journal:  Parasitol Res       Date:  2014-04-12       Impact factor: 2.289

4.  Cross-species prophylactic efficacy of Sm-p80-based vaccine and intracellular localization of Sm-p80/Sm-p80 ortholog proteins during development in Schistosoma mansoni, Schistosoma japonicum, and Schistosoma haematobium.

Authors:  Adebayo J Molehin; Souad R Sennoune; Weidong Zhang; Juan U Rojo; Arif J Siddiqui; Karlie A Herrera; Laura Johnson; Justin Sudduth; Jordan May; Afzal A Siddiqui
Journal:  Parasitol Res       Date:  2017-10-12       Impact factor: 2.289

5.  Complement plays a minimal role in Sm-p80-mediated protection against Schistosoma mansoni.

Authors:  Souvik Karmakar; Weidong Zhang; Gul Ahmad; Mayeen U Alam; Richard Winn; Workineh Torben; Loc Le; Kory A Tillery; Afzal A Siddiqui
Journal:  Hum Vaccin Immunother       Date:  2013-12-27       Impact factor: 3.452

6.  Sm29, but not Sm22.6 retains its ability to induce a protective immune response in mice previously exposed to a Schistosoma mansoni infection.

Authors:  Clarice Carvalho Alves; Neusa Araujo; Viviane Cristina Fernandes dos Santos; Flávia Bubula Couto; Natan R G Assis; Suellen B Morais; Sérgio Costa Oliveira; Cristina Toscano Fonseca
Journal:  PLoS Negl Trop Dis       Date:  2015-02-27

Review 7.  Eliminating Schistosomes through Vaccination: What are the Best Immune Weapons?

Authors:  Cristina Toscano Fonseca; Sergio Costa Oliveira; Clarice Carvalho Alves
Journal:  Front Immunol       Date:  2015-03-09       Impact factor: 7.561

8.  Distribution of Peripheral Memory T Follicular Helper Cells in Patients with Schistosomiasis Japonica.

Authors:  Xiaojun Chen; Wei Li; Yang Zhang; Xian Song; Lei Xu; Zhipeng Xu; Sha Zhou; Jifeng Zhu; Xin Jin; Feng Liu; Gengxin Chen; Chuan Su
Journal:  PLoS Negl Trop Dis       Date:  2015-08-18

9.  A vaccine consisting of Schistosoma mansoni cathepsin B formulated in Montanide ISA 720 VG induces high level protection against murine schistosomiasis.

Authors:  Alessandra Ricciardi; Kittipos Visitsunthorn; John P Dalton; Momar Ndao
Journal:  BMC Infect Dis       Date:  2016-03-05       Impact factor: 3.090

10.  Sm16, A Schistosoma mansoni Immunomodulatory Protein, Fails to Elicit a Protective Immune Response and Does Not Have an Essential Role in Parasite Survival in the Definitive Host.

Authors:  Wilma Patrícia de Oliveira Santos Bernardes; Juliano Michel de Araújo; Gardênia Braz Carvalho; Clarice Carvalho Alves; Aline Thaynara de Moura Coelho; Isabela Thamara Sabino Dutra; Sueleny Silva Ferreira Teixeira; Rosy Iara Maciel de Azambuja Ribeiro; Marina de Moraes Mourão; Rosiane Aparecida da Silva-Pereira; Cristina Toscano Fonseca
Journal:  J Immunol Res       Date:  2019-12-01       Impact factor: 4.818

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.